Princeton chemists led by Prof. Todd Hyster have found a way to make a naturally occurring enzyme take on a new, artificial role, which has significant implications for modern chemistry, including pharmaceutical production.
This review paper will cover recent advances in the development of chemotherapeutic agents against several metabolic targets for cancer therapy, including glucose transporters, hexokinase, pyruvate kinase M2, glutaminase, and isocitrate dehydrogenase.
The bottleneck of cationic antimicrobial peptides as anticancer therapeutics is their limited ability to penetrate cell membranes. Tokyo Medical and Dental University (TMDU) researchers discovered a cyclic decapeptide (termed peptide 1) that serves as a promising lead compound as a new intracellular delivery vehicle for therapeutically effective peptides. When conjugated with another membrane impermeable proapoptotic domain (PAD) peptide, the compound was found to have significantly inhibitory activity in cancer cell lines.
Opioids are powerful painkillers that act on the brain, but they have a range of harmful side effects including addiction. Researchers from the Max Planck Institute of Biochemistry in collaboration with researchers from the Medical University of Innsbruck, Austria, University of Innsbruck, and the Lewis Katz School of Medicine at Temple University, have developed a tool that gives deeper insights into the brain's response to opioids.
UBC researchers have matched small proteins, called peptides, with antibiotics so they can work together to combat hard-to-treat infections that don't respond well to drugs on their own.
A new study shows that a caffeine concentration equivalent to four cups of coffee promotes the movement of a regulatory protein into mitochondria, enhancing their function and protecting cardiovascular cells from damage. The work, by Judith Haendeler and Joachim Altschmied of the Medical Faculty, Heinrich-Heine-University and the IUF-Leibniz Research Institute for Environmental Medicine in Duesseldorf, Germany, and colleagues, publishes June 21 in the open access journal PLOS Biology.
A new SLAS Discovery review article summarizes new methods of fragment-based lead discovery (FBLD) to identify new compounds as potential antibiotics. It explains how FBLD works and illustrates its advantages over conventional high-throughput screening.
The lungs can be a difficult organ to biopsy with a needle, so identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic. Knowing how and when to use a liquid biopsy is critically important and led global experts at the International Association for the Study of Lung Cancer (IASLC) to issue 'The IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC),' available in the Journal of Thoracic Oncology.
This approach is being assessed by Public Health England for its potential to routinely test all meningococcal disease cases.
'This new method should allow us to explore a large 'chemical space' that had been essentially off-limits.'